MC
NKGN

Meteora Capital’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Meteora Capital’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$193K Hold
2,755,935
– – 0.01% 196
2025
Q4 		$138K Hold
2,755,935
– – 0.01% 212
2025
Q3 		$303K Buy
+2,755,935
New +$303K 0.03% 148
2025
Q1 		– Sell
-2,772,145
Closed -$1.82M – 186
2024
Q4 		$1.82M Buy
2,772,145
+1,887,400
+213% +$769K 0.6% 46
2024
Q3 		$334K Sell
884,745
-283,245
-24% -$251K 0.09% 109
2024
Q2 		$1.48M Sell
1,167,990
-39,626
-3% -$55.4K 0.27% 91
2024
Q1 		$2.28M Sell
1,207,616
-389,201
-24% -$747K 0.39% 66
2023
Q4 		$4.39M Sell
1,596,817
-525,898
-25% -$1.7M 0.75% 34
2023
Q3 		$17.6M Buy
2,122,715
+2,067,811
+3,766% +$21M 3% 4
2023
Q2 		$567K Buy
54,904
+309
+0.6% +$3.16K 0.1% 157
2023
Q1 		$553K Buy
54,595
+34,746
+175% +$351K 0.07% 186
2022
Q4 		$197K Sell
19,849
-14,897
-43% -$147K 0.04% 174
2022
Q3 		$339K Buy
+34,746
New +$339K 0.09% 166

Meteora Capital's NKGN Position: Q1 2026 in Review

Meteora Capital held its NKGen Biotech, Inc. Common Stock (NKGN) position steady in Q1 2026 at 2,755,935 shares worth $193K. The position accounts for 0.01% of the portfolio, ranked #196.

Meteora Capital first reported a position in NKGN in Q3 2022 and has held it in 13 quarters since. The position peaked at $17.6M in Q3 2023. 1 fund tracked by Wall St. Rank holds NKGN as of Q1 2026.

  • Meteora Capital held 2,755,935 shares of NKGen Biotech, Inc. Common Stock worth $193K as of Q1 2026.
  • Meteora Capital left its NKGen Biotech, Inc. Common Stock share count unchanged in Q1 2026.
  • NKGen Biotech, Inc. Common Stock made up 0.01% of Meteora Capital's portfolio in Q1 2026, its #196 holding.
  • Meteora Capital first reported a position in NKGen Biotech, Inc. Common Stock in Q3 2022 and has held it in 13 quarters since.
  • Meteora Capital's NKGen Biotech, Inc. Common Stock position peaked at $17.6M in Q3 2023.
  • 1 fund tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q1 2026.

Based on Meteora Capital's 13F filing for Q1 2026, filed 15 May 2026.